Efficacy and tolerability of agomelatine in the treatment of depression

Depression is a severe and usually recurrent mental disorder which often leads to a significant impairment of everyday functioning, a reduced quality of life, and also great suffering of the patients. The treatment of a depressive disorder is not only limited to acute treatment; it also requires prolonged management. Patient compliance is of utmost importance. Unpleasant adverse effects and their impact on everyday living often lead to a premature discontinuation of antidepressant treatment and result in an unfavorable treatment outcome. The new antidepressant agomelatine, a melatonergic MT1/MT2 agonist and 5-HT2C receptor antagonist, has exhibited good antidepressant efficacy in acute, short-term, and long-term treatment. The adverse effect profile of agomelatine has been proven to be favorable and comparable to placebo, which is very important for good treatment compliance and adherence.

• Publication year

  2014

• Venue

  Patient Preference and Adherence

• Publication date

  2014-05-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/PPA.S42789PMID 24833894PMCID 4014359
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The sex effects scale: pilot validation in a healthy population.

  2025cited by this paper
• Agomelatine: an agent against anhedonia and abulia?

  2015influential reference
• Antidepressant-induced liver injury: a review for clinicians.

  2014influential reference
• Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials.

  2013cited by this paper
• Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review

  2013cited by this paper
• Agomelatine versus other antidepressive agents for major depression.

  2013influential reference
• Agomelatine and Hepatotoxicity: Implications of Cumulated Data Derived from Spontaneous Reports of Adverse Drug Reactions

  2013influential reference
• Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control

  2013cited by this paper
• A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline

  2013influential reference
• The Antidepressant Agomelatine in Daily Practice: Results of the Non-Interventional Study VIVALDI

  2012cited by this paper
• The economic cost of brain disorders in Europe

  2012cited by this paper
• Agomelatine Versus Venlafaxine XR in the Treatment of Anhedonia in Major Depressive Disorder: A Pilot Study

  2012influential reference
• Circadian dimension and severity of depression.

  2012cited by this paper
• Circadian rhythms and mood regulation: insights from pre-clinical models.

  2011cited by this paper
• Major depressive disorder, anhedonia, and agomelatine: An open-label study

  2011cited by this paper
• The effects of agomelatine on sexual function in depressed patients and healthy volunteers

  2011cited by this paper
• Agomelatine: a narrative review.

  2011influential reference
• Genetics of circadian rhythms and mood spectrum disorders.

  2011influential reference
• Agomelatine: a novel antidepressant.

  2011cited by this paper
• Novel melatonin-based therapies: potential advances in the treatment of major depression.

  2011influential reference
• Implementing interpersonal and social rhythm therapy for mood disorders across a continuum of care.

  2011cited by this paper
• Clinical parameters of circadian rhythms in affective disorders.

  2011cited by this paper
• Agomelatine in the treatment of major depressive disorder

  2010influential reference
• Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration

  2010cited by this paper
• Review: Clock genes at the heart of depression

  2010cited by this paper
• Agomelatine for treatment of depression

  2010cited by this paper
• Agomelatine, the first melatonergic antidepressant: discovery, characterization and development

  2010influential reference
• Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.

  2010cited by this paper
• Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

  2010cited by this paper
• PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder

  2010cited by this paper
• Effect of Light on Human Circadian Physiology.

  2009cited by this paper
• Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus

  2009cited by this paper
• Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration

  2009influential reference
• Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.

  2009influential reference
• Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder.

  2009cited by this paper
• The global burden of mental disorders: An update from the WHO World Mental Health (WMH) Surveys*

  2009cited by this paper
• Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons.

  2008cited by this paper
• The genetics of mammalian circadian order and disorder: implications for physiology and disease

  2008cited by this paper
• A Double-Blind Comparison of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between Agomelatine and Venlafaxine XR

  2008cited by this paper
• Diurnal variation of depressive symptoms

  2008cited by this paper
• Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms

  2008cited by this paper
• Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target.

  2007influential reference
• Major depressive disorder, sleep EEG and agomelatine: an open-label study.

  2007cited by this paper
• Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism.

  2007cited by this paper
• The interaction between the internal clock and antidepressant efficacy

  2007influential reference
• Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.

  2007cited by this paper
• Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.

  2007cited by this paper
• Head to Head: Is depression overdiagnosed? No

  2007cited by this paper
• Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.

  2006cited by this paper
• Sleep and depression.

  2006cited by this paper
• Medical management of depression.

  2006cited by this paper
• The medical management of depression.

  2005cited by this paper
• Sleep and depression.

  2005cited by this paper
• The relationship between antidepressant medication use and rate of suicide.

  2005cited by this paper
• Sleep complaints among older general practice patients: association with depression.

  2005cited by this paper
• Antidepressants and sleep: a qualitative review of the literature.

  2005cited by this paper
• Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study

  2005cited by this paper
• Daytime sleepiness and insomnia as correlates of depression.

  2004cited by this paper
• The Neurobiology of Depression: Perspectives from Animal and Human Sleep Studies

  2003cited by this paper
• Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.

  2003cited by this paper
• Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd ed.

  2002cited by this paper
• Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

  2002cited by this paper
• Antidepressants in clinical practice: limitations of assessment methods and drug response

  2001cited by this paper
• Use of slow-release melatonin in treatment-resistant depression.

  2000cited by this paper
• Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans

  1995cited by this paper
• submit your manuscript | www.dovepress.com

  year unknowncited by this paper

• Do sex and gender matter in the pharmacological treatment of depression?

  2025cites this paper
• The Interplay between MiR-134/BDNF and LKB1/AMPK/SIRT1 Accentuates the Antidepressant Efficacy of Empagliflozin in Ovariectomized Rats.

  2024cites this paper
• Highly sensitive electrochemical determination of agomelatine in biological samples based on Cu nanoparticles/Schiff base network1 modified glassy carbon electrode: DFT and experimental studies.

  2024cites this paper
• Participation of Ca2+-Calmodulin–Dependent Protein Kinase II in the Antidepressant-Like Effects of Melatonin

  2024cites this paper
• The effects of agomelatine, fluoxetine, and sertraline on rat bladder contraction in vitro

  2023cites this paper
• EFFECT OF AGOMELATINE AND SERTRALINE ON PATIENTS WITH MAJOR DEPRESSIVE DISORDERS AND CHRONIC KIDNEY DISEASE: A RANDOMIZED CONTROLLED TRIAL

  2022cites this paper
• Cross talk mechanism of disturbed sleep patterns in neurological and psychological disorders.

  2022cites this paper
• Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review

  2021cites this paper
• 17β-Estradiol augments the neuroprotective effect of agomelatine in depressive- and anxiety-like behaviors in ovariectomized rats

  2020cites this paper
• Kisspeptin and RF9 prevent paroxetine‐induced changes in some parameters of seminal vesicle fluid in the male rats

  2020cites this paper
• Antidepressant metabolomics study of Danzhi Xiaoyao powder on Rat Model of Chronic Unpredictable Mild Stress(CUMS).

  2020cites this paper
• Optimal doses of antidepressants in dependence on age: Combined covariate actions in Bayesian network meta-analysis

  2020cites this paper
• Nine traditional Chinese herbal formulas for the treatment of depression: an ethnopharmacology, phytochemistry, and pharmacology review

  2019cites this paper
• Melatonin receptor stimulation by agomelatine prevents Aβ-induced tau phosphorylation and oxidative damage in PC12 cells

  2019cites this paper
• Agomelatine in the management of depression

  2018cites this paper
• Agomelatine pretreatment prevents development of hyperglycemia and hypoinsulinemia in streptozotocin‐induced diabetes in mice

  2018cites this paper
• Melatonin and Major Neurocognitive Disorders: Beyond the Management of Sleep and Circadian Rhythm Dysfunction

  2018cites this paper
• Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.

  2017cites this paper
• Bioequivalence and Pharmacokinetic Profiles of Agomelatine 25-mg Tablets in Healthy Chinese Subjects: A Four-Way Replicate Crossover Study Demonstrating High Intra- and Inter-Individual Variations.

  2017cites this paper
• Insomnia and dementia: is agomelatine treatment helpful? Case report and review of the literature

  2016cites this paper
• Nine traditional Chinese herbal formulas for the treatment of depression: an ethnopharmacology, phytochemistry, and pharmacology review

  2016cites this paper
• Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice

  2016cites this paper
• Augmentation of antidepressant effects of venlafaxine by agomelatine in mice are independent of kynurenine pathway.

  2016cites this paper
• Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder

  2016cites this paper
• COMPARATIVE REVIEW OF A NOVEL MELATONERGIC ANTIDEPRESSANT DRUG- AGOMELATINE

  2015cites this paper
• Agomelatin – Update aktueller Daten 2015

  2015cites this paper
• Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers

  2015cites this paper
• Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial

  2015cites this paper
• New antidepressant drugs for new depressions.

  2014cites this paper
• Searching the Cytochrome P450 Enzymes for the Metabolism of Meranzin Hydrate: A Prospective Antidepressant Originating from Chaihu-Shugan-San

  2014cites this paper